Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Profit & Loss 
Valuation 
Analyst Note 
Balance Sheet 
Cash Flow 
Financial Ratio 
Qtr. Results 
News 
About
Albert David Ltd (ALBERTDAVD)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524075 NSE: ALBERTDAVD Pharmaceuticals & Drugs | Small Cap | Albert David Share Price
₹685.75 -2.45 (-0.36%)
As on 23-Jul'26 16:59
Albert David Ltd (ALBERTDAVD)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524075 NSE: ALBERTDAVD Pharmaceuticals & Drugs | Small Cap | Albert David Share Price
₹685.75 -2.45 (-0.36%)
As on 23-Jul'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹391 Cr.
Current Price
₹685.8
52-Week Low / High
₹581 / 924
TTM EPS
₹-2.6
TTM Sales
₹334 Cr.
Book Value per Share
₹686
P/E Ratio
0.00
Lower than its 5-year historical median
Industry PE
53.4
Price to Book (P/B)
1.00
Lower than its 5-year historical median
Price to Sales (P/S)
1.17
Lower than its 5-year historical median
EV/EBITDA
29.34
Higher than its 5-year historical median
Dividend Yield
0.73%
Profitability Efficiency
Return on Equity (ROE)
-0.38%
Underperforms industry median
Return on Capital Employed (ROCE)
0.83%
Underperforms industry median
Return on Assets (ROA)
-0.24%
Operating Profit Margin
3%
Net Profit Margin
-0.45%
Gross Profit Margin
2.9%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-3.52%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
81.65%
Net Profit Growth (1 Year)
-
-108.66%
Asset Quality
Promoter Holding
62.24%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹386 Cr.
Equity
₹5.7 Cr.
Face Value
₹10
All Time Low / High
₹3.15 / 1752.95
Check Before You Invest
Quality
Somewhat GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Albert David Ltd a good quality company?
Albert David Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Albert David Ltd performance compare with that of its Peers?
Revenue growth of Albert David Ltd vs industry peers?
Albert David Ltd revenue CAGR is 1.51%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Albert David Ltd?
Promoters hold 62.24% of the Albert David Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Albert David Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 8.8% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Albert David Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 14.3% | 7.9% | 20.6% | 13.7% | 12% | 18.1% | 17.1% | 27.9% | 6.5% | 0.8% | - |
| Value Creation Index ⓘ | 0.0 | -0.4 | 0.5 | 0.0 | -0.1 | 0.3 | 0.2 | 1.0 | -0.5 | -0.9 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 295 | 290 | 317 | 321 | 247 | 314 | 342 | 362 | 346 | 334 | 334 |
| Sales YoY Gr. | - | -1.7% | 9.3% | 1.1% | -22.9% | 26.7% | 9% | 6.1% | -4.6% | -3.5% | - |
| Adj EPS ⓘ | 23.7 | 11.4 | 26 | 36.4 | 37 | 57.1 | 62.9 | 130.3 | 30.8 | 1.4 | -2.6 |
| YoY Gr. | - | -52% | 128.7% | 39.8% | 1.6% | 54.4% | 10.1% | 107.2% | -76.3% | -95.4% | - |
| BVPS (₹) ⓘ | 320.7 | 325.8 | 368.7 | 390.4 | 428.2 | 489.7 | 545.9 | 671.1 | 687.7 | 686 | 686 |
| Adj Net Profit ⓘ | 13.5 | 6.5 | 14.9 | 20.8 | 21.1 | 32.6 | 35.9 | 74.3 | 17.6 | 0.8 | -1 |
| Cash Flow from Ops. ⓘ | 19.9 | 30 | 31.9 | 30.3 | 36.6 | 40.4 | 10.5 | 45.5 | -28.4 | -7.7 | - |
| Debt/CF from Ops. ⓘ | 1.5 | 0.9 | 0 | 0.1 | 0 | 0.1 | 0.5 | 0.1 | -0.4 | -3.7 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 1.4% | 6.2% | -0.8% | -3.5% | ||||
| Adj EPS ⓘ | -26.9% | -48% | -71.8% | -95.4% | ||||
| BVPSⓘ | 8.8% | 9.9% | 7.9% | -0.2% | ||||
| Share Price | 8.1% | 3.7% | -1.4% | -24.5% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 8.5 | 3.5 | 7.5 | 9.6 | 9 | 12.4 | 12.1 | 21.4 | 4.5 | 0.2 | -0.4 |
| Op. Profit Mgn % ⓘ | 6.6 | 5.9 | 9.4 | 10.6 | 7.8 | 13.1 | 13.2 | 13 | 1.2 | 3 | 1.6 |
| Net Profit Mgn % ⓘ | 4.6 | 2.2 | 4.7 | 6.5 | 8.5 | 10.4 | 10.5 | 20.5 | 5.1 | 0.2 | -0.5 |
| Debt to Equity ⓘ | 0.2 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 |
| Working Cap Days ⓘ | 194 | 212 | 193 | 190 | 227 | 183 | 201 | 201 | 232 | 259 | 201 |
| Cash Conv. Cycle ⓘ | 62 | 47 | 32 | 28 | 36 | 27 | 32 | 31 | 39 | 49 | 138 |
Profit And Loss
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 295 | 290 | 317 | 321 | 247 | 314 | 342 | 362 | 346 | 334 |
| Operating Expenses ⓘ + | 277 | 275 | 288 | 290 | 228 | 273 | 297 | 315 | 343 | 328 |
| Operating Profit ⓘ | 18 | 16 | 29 | 31 | 19 | 41 | 44 | 47 | 3 | 6 |
| Operating Profit Margin (%) | 6.1% | 5.4% | 9.2% | 9.5% | 7.8% | 13.1% | 13.0% | 13.0% | 0.9% | 1.7% |
| Other Income ⓘ + | 16 | 10 | 21 | 7 | 17 | 16 | 15 | 58 | 30 | 7 |
| Interest ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 3 |
| Depreciation ⓘ | 8 | 8 | 7 | 8 | 8 | 9 | 9 | 7 | 7 | 10 |
| Profit Before Tax ⓘ | 26 | 16 | 43 | 29 | 27 | 47 | 51 | 97 | 25 | 1 |
| Tax ⓘ | 10 | 6 | 16 | 10 | 5 | 12 | 15 | 22 | 8 | 2 |
| Profit After Tax | 16 | 10 | 27 | 19 | 22 | 35 | 36 | 75 | 17 | -1 |
| PAT Margin (%) | 5.4% | 3.4% | 8.4% | 6.0% | 9.0% | 11.3% | 10.6% | 20.8% | 5.0% | -0.5% |
| Adjusted EPS (₹) | 28.0 | 17.2 | 46.7 | 33.6 | 38.8 | 61.8 | 63.4 | 132.2 | 30.1 | -2.6 |
| Dividend Payout Ratio (%) | 19.70% | 31.90% | 12.90% | 20.80% | 15.50% | 14.60% | 14.20% | 8.70% | 16.60% | -190.90% |
Valuation of Albert David - Standalone
Analyst's Notes
No data found!
Balance Sheet
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 183 | 186 | 210 | 223 | 244 | 279 | 312 | 383 | 392 | 392 | |
| Debt + | 30 | 28 | 0 | 1 | 1 | 4 | 4 | 2 | 10 | 28 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 27 | 32 | 30 | 38 | 25 | 30 | 32 | 34 | 38 | 33 | |
| Others Liabilities ⓘ | 110 | 116 | 135 | 136 | 135 | 161 | 165 | 185 | 184 | 184 | |
| Total Liabilities ⓘ | 351 | 361 | 376 | 398 | 405 | 475 | 512 | 604 | 625 | 637 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 87 | 83 | 77 | 91 | 84 | 88 | 80 | 83 | 99 | 100 | |
| CWIP ⓘ | 9 | 5 | 5 | 2 | 1 | 1 | 3 | 7 | 2 | 21 | |
| Investments ⓘ | 59 | 68 | 113 | 122 | 138 | 183 | 193 | 273 | 260 | 243 | |
| Inventories | 51 | 43 | 44 | 43 | 36 | 39 | 51 | 44 | 64 | 58 | |
| Trade Receivables | 33 | 27 | 22 | 30 | 19 | 25 | 30 | 29 | 27 | 34 | |
| Cash Equivalents | 15 | 26 | 7 | 7 | 35 | 19 | 25 | 31 | 2 | 33 | |
| Others Assets ⓘ | 98 | 109 | 108 | 104 | 92 | 121 | 131 | 137 | 171 | 148 | |
| Total Assets ⓘ | 351 | 361 | 376 | 398 | 405 | 475 | 512 | 604 | 625 | 637 | |
Cash Flow
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 20 | 30 | 32 | 30 | 37 | 40 | 11 | 46 | -28 | -8 |
| Cash Flow From Investing Activity ⓘ + | -37 | -11 | -19 | -20 | -39 | -40 | -5 | -33 | 23 | -4 |
| Cash Flow From Financing Activity ⓘ + | 7 | -5 | -17 | -10 | -2 | -2 | -6 | -8 | 0 | 12 |
| Net Cash Flow ⓘ | -10 | 14 | -4 | -0 | -4 | -1 | -1 | 4 | -5 | -0 |
Financial Ratio
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 9.98 | 5.33 | 13.44 | 8.85 | 9.48 | 13.46 | 12.24 | 21.72 | 4.44 | -0.38 |
| ROCE (%) | 14.29 | 7.94 | 20.6 | 13.74 | 11.99 | 18.1 | 17.1 | 27.87 | 6.54 | 0.83 |
| Asset Turnover Ratio | 1 | 0.87 | 0.9 | 0.87 | 0.65 | 0.75 | 0.73 | 0.69 | 0.6 | 0.56 |
| PAT to CFO Conversion(x) | 1.25 | 3 | 1.19 | 1.58 | 1.68 | 1.14 | 0.31 | 0.61 | -1.65 | N/A |
| Working Capital Days | ||||||||||
| Receivable Days | 40.80 | 35.50 | 26.90 | 28.10 | 34.80 | 24.60 | 28 | 28.40 | 27.90 | 31.60 |
| Inventory Days | 59.10 | 55.20 | 47.80 | 46.90 | 55 | 41.40 | 45.50 | 44.90 | 52.80 | 63.10 |
| Payable Days | 166.50 | 180.80 | 149.40 | 166.80 | 164.80 | 115.20 | 130.60 | 132.70 | 112.20 | 112.30 |
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Albert David Ltd FAQs
The current trading price of Albert David on 23-Jul-2026 16:59 is ₹685.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Jul-2026 the market cap of Albert David stood at ₹391.4 Cr
The latest P/E ratio of Albert David as of 22-Jul-2026 is 0.00.
The latest P/B ratio of Albert David as of 22-Jul-2026 is 1.00.
The 52-week high of Albert David is ₹924.4 and the 52-week low is ₹581.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Albert David is ₹334 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Albert David Ltd is a average quality company.
The key valuation ratios of Albert David Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Albert David Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Albert David Ltd
Albert David (ADL), a prominent pharmaceutical company, is distinguished in the field of manufacturing pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs. The company is based in Kolkata, India. It belongs to the renowned industrial house of Kolkata, the “Kothari Group, India.” Equipped with cutting-edge research and development capabilities and scientific expertise, the company develops new products for the demanding global marketplace.
The company has pioneered many modern techniques in its research work and has implemented innovative ideas. Innovation is a core part of the company’s culture and guides all its strategies. The company has state-of-the-art manufacturing facilities in different parts of the country. The Kolkata manufacturing unit is a WHO-GMP-approved facility and includes a Small Volume Parenteral suite compliant with USFDA cGMP requirements. Another unit is located in Ghaziabad, near New Delhi, is an ISO 9001:2008 certified plant.
The company’s core strength lies in its vibrant team of employees and its continuous effort to bring out the best and become the best. With an extensive network of stockists across various parts of the country, the company is able to make its products available in every corner of India. The company also has a significant presence in Southeast Asia, Africa, the Middle East, Europe, the USA, and Latin America.
The company is also in strategic collaboration with academic institutes such as the Indian Institute of Chemical Biology (CSIR) and the Department of Biotechnology, University of Calcutta, for research partnerships.
Business area of the company
The company is a leading, fast growing and a professionally managed pharmaceutical company in India.
Products
Formulations
- Parenterals
- Oral / Enteral
- Topical Agents
- Vision Care
Bulk Drugs
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
